SOPHIA ANTIPOLIS, FRANCE--(Marketwire - February 07, 2013) -
Nicox to present at the 15(th) Annual BIO CEO & Investor Conference
...................................
Nicox S.A. (EURONEXT PARIS: COX), a new international player in the
ophthalmic market, today announced that Michele Garufi, Chairman and CEO,
will
be presenting at the 15th Annual BIO CEO & Investor Conference in New York,
NY,
on Tuesday February 12(th) at 3:30pm EST.
Michele Garufi will give an overview of the Company's growth strategy and
will
highlight the corporate milestones and business development opportunities
of
Nicox.
Michele Garufi will also be available for one-on-one meetings at the
conference.
The presentation will be uploaded on Nicox website www.nicox.com on
Wednesday
February 13(th). No live audio broadcast or archived recording will be
available.
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a
new mid-sized international player in the ophthalmic market by
building a diversified
portfolio of innovative therapies and diagnostic tools. With a
heritage of
scientific, business development and commercial expertise, the Nicox
team is
focused on developing and marketing novel pharmaceuticals and diagnostic
devices
that can help people to enhance their sight. In the United States, Nicox
markets
AdenoPlus™, a test for the differential diagnosis of acute
conjunctivitis in-licensed from RPS®.
The Company's pipeline includes latanoprostene bunod, a
novel drug-candidate based on Nicox's proprietary nitric oxide (NO)-
donating R&D platform, developed
in collaboration with Bausch + Lomb for the potential treatment of
glaucoma and
ocular hypertension. Further NO-donating compounds are under
development in non-ophthalmic indications, notably through partners,
including Merck (known as MSD
outside the United States and Canada) and Ferrer.
Nicox S.A. is headquartered in France and is listed on Euronext
Paris
(Compartment B: Small Caps). For more information please visit
www.nicox.com.
...................................
...................................
This communication may contain certain forward-looking statements.
Although the
Company believes its expectations are based on reasonable assumptions,
these
forward-looking statements are subject to numerous risks and
uncertainties,
which could cause actual results to differ materially from those
anticipated in
the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's
business are
presented in the 4th chapter of the « Document de
référence, rapport financier
annuel et rapport de gestion 2011 » filed with the French
Autorité des Marchés
Financiers (AMF) on February 29, 2012 and available on Nicox's
website
(www.nicox.com) and on the AMF's website (www.amf-france.org).
...................................
Nicox S.A.
Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia
Antipolis |
06560 Valbonne | France
T: +33 (0)4 97 24 53 00 | F: +33 (0)4 97 24 53 99
www.nicox.com
Nicox to present at the 15th Annual BIO CEO & Investor Conference:
http://hugin.info/143509/R/1676341/546346.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE
[HUG#1676341]
